Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael Kasperkiewicz

Showing results (11-20 of 88) with videos related to

Pageof 9
Sort By:
Journal of the European Academy of Dermatology and Venereology : JEADV|August 22, 2022
Rituximab in immunobullous disorders during the COVID-19 pandemic: A systematic review of observational studiesMichael Kasperkiewicz, David T Woodley
Journal of the American Academy of Dermatology|April 27, 2021
Association between vaccination and autoimmune bullous diseases: A systematic reviewMichael Kasperkiewicz, David T Woodley
Autoimmunity Reviews|February 4, 2023
COVID-19 and autoimmune bullous diseases: Lessons learnedMichael Kasperkiewicz, David T Woodley
Frontiers in Medicine|January 6, 2022
Case Report: Circulating Anti-SARS-CoV-2 Antibodies Do Not Cross-React With Pemphigus or Pemphigoid AutoantigensMichael Kasperkiewicz, Marta Bednarek, Stefan Tukaj
Experimental Dermatology|May 19, 2015
Heat shock protein 90: a pathophysiological factor and novel treatment target in autoimmune bullous skin diseasesStefan Tukaj, Detlef Zillikens, Michael Kasperkiewicz
Clinics in Dermatology|December 6, 2011
Current therapy of the pemphigus groupMichael Kasperkiewicz, Enno Schmidt, Detlef Zillikens
Lancet (London, England)|September 10, 2019
PemphigusEnno Schmidt, Michael Kasperkiewicz, Pascal Joly
Journal of the American Academy of Dermatology|January 30, 2014
Pemphigus herpetiformis: from first description until nowMichael Kasperkiewicz, Cezary Kowalewski, Stefania Jabłońska
JAAD International|December 15, 2025
Dupilumab for bullous pemphigoid: Umbrella review of systematic reviews and meta-analysesMishek Thapa, Brianna Green, Michael Kasperkiewicz
Journal of Inflammation (London, England)|April 4, 2014
Inhibitory effects of heat shock protein 90 blockade on proinflammatory human Th1 and Th17 cell subpopulationsStefan Tukaj, Detlef Zillikens, Michael Kasperkiewicz
Pageof 9

Showing results (11-20 of 88) with videos related to

Sort By:
Pageof 9
Journal of the European Academy of Dermatology and Venereology : JEADV|August 22, 2022
Rituximab in immunobullous disorders during the COVID-19 pandemic: A systematic review of observational studiesMichael Kasperkiewicz, David T Woodley
Journal of the American Academy of Dermatology|April 27, 2021
Association between vaccination and autoimmune bullous diseases: A systematic reviewMichael Kasperkiewicz, David T Woodley
Autoimmunity Reviews|February 4, 2023
COVID-19 and autoimmune bullous diseases: Lessons learnedMichael Kasperkiewicz, David T Woodley
Frontiers in Medicine|January 6, 2022
Case Report: Circulating Anti-SARS-CoV-2 Antibodies Do Not Cross-React With Pemphigus or Pemphigoid AutoantigensMichael Kasperkiewicz, Marta Bednarek, Stefan Tukaj
Experimental Dermatology|May 19, 2015
Heat shock protein 90: a pathophysiological factor and novel treatment target in autoimmune bullous skin diseasesStefan Tukaj, Detlef Zillikens, Michael Kasperkiewicz
Clinics in Dermatology|December 6, 2011
Current therapy of the pemphigus groupMichael Kasperkiewicz, Enno Schmidt, Detlef Zillikens
Lancet (London, England)|September 10, 2019
PemphigusEnno Schmidt, Michael Kasperkiewicz, Pascal Joly
Journal of the American Academy of Dermatology|January 30, 2014
Pemphigus herpetiformis: from first description until nowMichael Kasperkiewicz, Cezary Kowalewski, Stefania Jabłońska
JAAD International|December 15, 2025
Dupilumab for bullous pemphigoid: Umbrella review of systematic reviews and meta-analysesMishek Thapa, Brianna Green, Michael Kasperkiewicz
Journal of Inflammation (London, England)|April 4, 2014
Inhibitory effects of heat shock protein 90 blockade on proinflammatory human Th1 and Th17 cell subpopulationsStefan Tukaj, Detlef Zillikens, Michael Kasperkiewicz
Pageof 9